Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.57 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HRH2 | P25021 | 4/20 | 0.46 |
| ▸ | HRH1 | P35367 | 4/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13102176 | 1.00 | CTSK (0.57) | CTSKKCNA3CA1CA2HSD11B1 | |
| SCHEMBL10280626 | 1.00 | CTSK (0.57) | CTSKKCNA3CA1CA2HSD11B1 | |
| SCHEMBL29255478 | 0.92 | CA1 (0.56) | CTSKKCNA3CA1CA2HSD11B1 | |
| SCHEMBL21733136 | 0.92 | CA1 (0.56) | CTSKKCNA3CA1CA2HSD11B1 | |
| SCHEMBL12971748 | 0.91 | KCNA3 (0.57) | CTSKKCNA3CA1CA2DRD2 | |
| SCHEMBL13583571 | 0.89 | CTSK (0.57) | CTSKKCNA3CA1CA2HSD11B1 | |
| SCHEMBL18530346 | 0.89 | CTSK (0.57) | CTSKKCNA3CA1CA2HSD11B1 | |
| SCHEMBL13583572 | 0.89 | CTSK (0.57) | CTSKKCNA3CA1CA2HSD11B1 | |
| SCHEMBL12321230 | 0.88 | CTSK (0.59) | CTSKKCNA3CA1CA2HSD11B1 | |
| SCHEMBL3544236 | 0.88 | CTSK (0.59) | CTSKKCNA3CA1CA2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349839-B2 | Inhibitors of HIV replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-08 | — | — | US | disclosed |
| US-8349839-B2 | Inhibitors of HIV replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-08 | — | — | US | disclosed |
| US-20100261714-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261714-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261714-A1 | INHIBITORS OF HIV REPLICATION | RTF2, POLR1A, REV1 | CTSK 2380/4885KCNA3 4131/4885CA1 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.